The epidemiology of mycotic vulvovaginitis and the use of antifungal agents in suspected mycotic vulvovaginitis and its implications for clinical practice

West Indian Medical Journal

Volumn 54, Issue 3, 2005, Pages 192-195

  Jackson, Sandra T ^a   Mullings, A M ^a   Rainford, L ^a   Miller, A ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; CLOTRIDERM; CLOTRIMAZOLE; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; POLYENE; PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; CANDIDA TROPICALIS; CARIBBEAN ISLANDS; CHLORELLA; CLINICAL PRACTICE; CRYPTOCOCCUS; CRYPTOCOCCUS ALBIDUS; DIAGNOSTIC ACCURACY; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MYCOSIS; OPPORTUNISTIC INFECTION; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PROTOTHECA WICKERHAMII; REVIEW; TREATMENT INDICATION; VULVOVAGINITIS; YEAST;

EID: 25144432862     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0043-31442005000300007     Document Type: Review

References (13)

1. Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 470-4.
2. Sobel JD. Vulvovaginitis: when Candida becomes a problem. Dermatol Clin 1998; 16: 763-8.
3. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C albicans. Clinical Microbiol Rev 1999; 12: 80-96.
4. Sobel JD. Treatment of vaginal candida infections. Expert Opin Pharmacother 2002; 3: 1059-65.
5. Martins MD. Antifungal Drug Resistance: A Focus on Candida. Clinical Updates, National Foundation of Infectious Diseases 1997; 1: 3 http://www.nfid.org/publications/clinicalupdates/fungal /candida.html.
6. Denning DW. Fortnightly Review: Management of genital candidiasis. Brit Med J 1997; 310: 1241-44 - http:/bmj.bmjjournals.com/cgi/content/full/310/6989/1241.
7. McCaig LF, McNeil MM. Trends in prescribing for vulvovaginal candidiasis in the United States. Pharmacoepidemiology and Drug Safety (in press) - http://www3.interscience.wiley.com.
8. Larone DH. Medically Important Fungi - A guide to identification, 3rd ed. New York, NY: ASM Press; 1995: 209-252.
9. Cruz O. Species distribution and antifungal susceptibility profile of Candida spp. Bloodstream isolates from Latin American Hospitals. Mem Inst Oswaldo Cruz 2003; 98: 401-5.
10. Favel A, Michel-Nguyen A, Datry A, Challier A, Leclerc F, Chastin C et al. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J Antimicrob Chemother 2004; 53: 526-9.
11. Garcia Figueroa RG, Sauceda L, Ramirez Palacios D, Cruz Talonia F, Romero Cabello R. effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis. Ginecol Obstet Mex 2000; 68: 154-9.
12. Kantrow SM, Boyd AS. Protothecosis. Dermatol Clin 2003; 21: 249-55.
13. Sugita T, Takashima M, Ikeda R, Nakase T, Shinoda T. Intraspecies diversity of Cryptococcus albidus isolated from humans as revealed by sequences of the internal transcribed spacer regions. Microbiol Immunol 2001; 45: 291-7.